The research team, led by investigators affiliated with Heilongjiang University of Chinese Medicine, took an unusually systematic approach. Because PCOS is a heterogeneous, multifactorial disorder and because traditional herbal formulas contain dozens of chemically active compounds acting on many targets simultaneously, the researchers first turned to network pharmacology. This computational strategy treats a disease and a drug as vast interaction networks and searches for the points where they overlap. The team screened the chemical constituents of BHF’s five herbs—Huang Qi (Astragalus membranaceus), Yin Yang Huo (Herba epimedii), Cang Zhu (Rhizoma atractylodis), Fu Ling (Poria cocos), and Dan Shen (Salvia miltiorrhiza)—using the TCMSP database, applying strict filters for oral bioavailability and drug-likeness. The screen yielded 101 active chemical components and 218 predicted protein targets.

Cross-referencing those drug targets against 5,836 PCOS-related targets harvested from the GeneCards and OMIM databases produced a set of 169 intersecting targets. From there, the researchers built a herb–component–target network in Cytoscape and ranked the ingredients by their degree values, a topological measure of how many other network nodes a given compound connects to. Luteolin, a flavonoid with 116 connections, topped the list, followed by wogonin, tanshinone IIA, formononetin, isorhamnetin, and several other molecules with documented anti-inflammatory and metabolic activity. Protein–protein interaction analysis then distilled the target network down to ten hub proteins: AKT1, TNF, IL6, TP53, ESR1, CASP3, EGFR, IL1B, PTGS2, and MMP9—names that will be immediately familiar to anyone who studies inflammation, apoptosis, insulin signaling, or ovarian steroidogenesis.

Enrichment analysis added a pathway-level view. The intersecting targets clustered in the AGE-RAGE signaling pathway in diabetic complications, the IL-17 and MAPK pathways, estrogen signaling, insulin resistance, and—most relevant to this study—the NF-κB signaling pathway. To probe whether the predicted compounds could actually engage their predicted targets, the team performed molecular docking with AutoDock Vina across one hundred compound–protein pairs. Sixty-six of these interactions showed strong binding affinity below −7.0 kcal/mol, indicating thermodynamically stable ligand–receptor complexes. Notably, tanshinone IIA, a diterpenoid from Dan Shen, bound PTGS2—the gene encoding cyclooxygenase-2—more tightly than any other pairing tested, flagging it as a potential lead compound.

Computational predictions, however, are only hypotheses until they meet wet-lab reality. To validate the network findings, the researchers used letrozole, an aromatase inhibitor, to induce PCOS in female Wistar rats via continuous-release pellets. Critically, they examined the animals at two time points—six weeks and twelve weeks after pellet implantation—to capture the dynamic evolution of the disease rather than a single endpoint. The letrozole model reproduced the metabolic and reproductive abnormalities seen in clinical PCOS: treated rats gained significantly more weight, accumulated more inguinal fat, and showed elevated fasting blood glucose compared with controls, with all measures worsening between the six- and twelve-week marks. Histology told a parallel story. While the ovaries of early-stage rats looked largely normal, the twelve-week group developed frank cystic follicular dilation, follicular atresia, and thinning of the granulosa cell layers—textbook signs of established PCOS.

The inflammatory signature emerged early and deepened over time. Immunohistochemistry revealed increased TLR4 and NF-κB protein staining in both ovarian and inguinal fat tissues of the twelve-week model, and a qPCR array of ninety-two NF-κB signaling targets detected significant shifts in genes including ACTB, C3, CXCL3, NQO1, and SELP. When the team isolated granulosa cells—the somatic cells that nurture developing oocytes and are essential for ovulation—they found dramatically elevated secretion of TNF-α, IL-1β, IL-6, IL-8, lipopolysaccharide-binding protein, LPS itself, CD14, and high-sensitivity C-reactive protein. Several of these markers, including IL-1β, IL-6, IL-8, and LPS, rose further between the six- and twelve-week stages, confirming that the inflammatory microenvironment of the PCOS ovary is not static but progressively escalating. The LPS–LBP–CD14 module is particularly significant mechanistically, because this triad is the canonical activator of TLR4, the innate immune receptor that switches on NF-κB and triggers the transcriptional program of chronic inflammation.

Enter the herbal formula. The researchers prepared BHF-containing serum by dosing healthy rats with the decoction and collecting their blood, then co-cultured this serum with granulosa cells isolated from the PCOS animals. The results were striking. In cells from six-week PCOS rats, BHF serum significantly reduced all eight inflammatory markers compared with cells treated with control serum, essentially reversing the heightened inflammatory state. In cells from twelve-week rats, BHF again lowered TNF-α, IL-1β, IL-6, IL-8, LBP, LPS, CD14, and hsCRP—but the reduction was only partial, and treated diseased cells still secreted significantly more inflammatory factors than treated healthy cells. In other words, the formula could suppress inflammation at both stages, but early-stage disease responded far more completely.

This stage-dependence is arguably the study’s most important translational message. It suggests that the chronic low-grade inflammatory state in PCOS precedes the full establishment of the syndrome and may actively contribute to its progression, and that therapeutic windows matter: once the inflammatory loop becomes entrenched, even a multi-target intervention cannot fully unwind it. The finding echoes a core principle of traditional Chinese medicine—“preventing disease before it progresses”—and aligns with the modern concept of early intervention in chronic inflammatory and metabolic disease. Because NF-κB sits at the hub of the cytokine network, feeding back on its own activation through TNF-α and sustaining IL-6 signaling via JAK/STAT3, breaking the loop early may prevent the self-perpetuating inflammation that disrupts granulosa cell steroidogenesis and ultimately ovulation itself.

The authors are appropriately candid about the limitations. The work was conducted entirely in rats and isolated cells; the letrozole model recapitulates only part of the heterogeneous human phenotype; TLR4/NF-κB activation was assessed by immunohistochemistry and gene expression rather than phospho-specific or loss-of-function experiments, so causation remains to be proven; the formula batch was not chemically fingerprinted; and hormonal endpoints such as testosterone and estrous cyclicity were not measured. Human validation—in granulosa cells, follicular fluid, and clinical cohorts—is the essential next step. Still, the convergence of computational prediction, molecular docking, and experimental data provides a rare level of mechanistic coherence for a multi-herb formula. If confirmed, BHF’s ability to modulate the TLR4/NF-κB axis could open a genuinely new direction for managing the inflammatory component of PCOS, one rooted in centuries of empirical practice but tested with thoroughly modern tools.

Subject of Research: Effects of the Bushen Huatan Formula on chronic low-grade inflammation in obese PCOS via the TLR4/NF-κB signaling pathway

Article Title: Bushen Huatan Formula Ameliorates Early Chronic Low‐Grade Inflammation in Obese PCOS Via the TLR4/NF‐κB Signaling Pathway: An Integrated Network Pharmacology and Experimental Study

Article References: Zhang, J., Gu, F., Li, Y., Feng, X., Kuang, H., Xu, F., & Sun, M. (2026). Bushen Huatan Formula Ameliorates Early Chronic Low‐Grade Inflammation in Obese PCOS Via the TLR4/NF‐κB Signaling Pathway: An Integrated Network Pharmacology and Experimental Study. Immunity, Inflammation and Disease, 14(9), Article e70518. https://doi.org/10.1002/iid3.70518

Image Credits: AI Generated

DOI: 10.1002/iid3.70518

Keywords: PCOS, chronic low-grade inflammation, Bushen Huatan Formula, TLR4/NF-κB pathway, network pharmacology, molecular docking, granulosa cells, traditional Chinese medicine, letrozole-induced rat model, inflammatory cytokines, ovarian inflammation, insulin resistance

The study, published in the journal Immunity, Inflammation and Disease, began with a rigorous chemical inventory of the decoction, which combines Angelicae Sinensis Radix, the root of Angelica sinensis, with Astragali Radix, the root of Astragalus membranaceus, in a precise 1:5 ratio. Using a Vanquish ultra-high-performance liquid chromatograph coupled to a QExactive HFX mass spectrometer, the researchers separated compounds on a Waters HSS T3 column at 40 degrees Celsius with a formic acid-acetonitrile gradient and electrospray ionization in both positive and negative ion modes. The analysis identified 104 compounds, dominated by phenylpropanoids and polyketides, lipids and lipid-like molecules, and organoheterocyclic compounds. This chemical fingerprint became the foundation for everything that followed.

With the compound list in hand, the team turned to network pharmacology, a computational approach that treats a multi-component herbal formula as a network of interacting molecules rather than a single active ingredient. Predicting targets for the identified compounds through SwissTargetPrediction yielded 499 drug-related targets, while searching GeneCards and OMIM for chronic glomerulonephritis produced 2,821 disease targets after redundancy removal. The intersection contained 166 overlapping targets, suggesting a substantial molecular interface between the formula and the disease. Building a protein-protein interaction network in Cytoscape and ranking targets with the CytoHubba MCC algorithm highlighted ten core targets, including B-cell lymphoma-2 (Bcl-2) and Caspase-3, both central players in apoptosis, the genetically programmed form of cell death.

Enrichment analysis through the Metascape platform pointed decisively toward the NF-κB signaling pathway, a master regulator of inflammation. To test whether this computational prediction reflected real biology, the researchers mined two independent gene expression datasets from the Gene Expression Omnibus, GSE116626 with 74 chronic glomerulonephritis samples and GSE104066 with 70 samples. After batch correction and standardization, differential expression analysis identified 414 significantly upregulated genes and 379 downregulated genes, and KEGG pathway analysis showed these genes were also significantly enriched in the NF-κB signaling pathway. The convergence of network pharmacology and patient gene expression data on the same pathway gave the team strong grounds to pursue experimental validation.

Molecular docking provided a structural bridge between chemistry and biology. Five active ingredients with high network centrality, 3-Hexen-1-ol O-β-d-glucopyranoside, 4-hydroxybenzoic acid, caffeic acid, calycosin, and lucidal, were docked against Bcl-2, Caspase-3, and TLR4. All fifteen compound-target pairs showed binding energies below the -5 kcal/mol threshold generally considered indicative of strong binding. Calycosin bound Caspase-3 at -7.2 kcal/mol, while lucidal achieved -8.5 kcal/mol against Caspase-3 and -7.8 kcal/mol against Bcl-2, stabilized by multiple hydrogen bonds with key amino acid residues. These docking scores suggested the herbal compounds could physically engage the apoptotic and inflammatory machinery implicated in the disease.

The first line of experimental evidence came from cell studies using HBZY-1 rat glomerular mesangial cells, whose abnormal behavior is a central driver of chronic glomerulonephritis progression. Rather than applying crude herbal extracts, the team prepared drug-containing serum by administering DBD to rats at three doses, 1.89, 3.78, and 7.56 grams per kilogram, then collecting the resulting serum, an approach that captures only the compounds that actually enter the bloodstream after metabolism. When LPS-stimulated mesangial cells were treated with DBD-containing serum, the abnormally elevated cell viability dropped, secretion of the anti-inflammatory cytokines IL-4 and IL-10 recovered, and Transwell assays showed markedly reduced migration and invasion. Immunofluorescence confirmed that TLR4 and NF-κB protein expression, which LPS had pushed upward, fell significantly after treatment.

The in vivo experiments used a classic adriamycin-induced rat model of chronic glomerulonephritis, established through two tail-vein injections and confirmed by 24-hour urinary protein exceeding 50 milligrams per kilogram. Rats receiving DBD for 30 days showed striking improvements across the board: 24-hour urine protein, serum creatinine, and blood urea nitrogen all fell significantly, while body weight recovered and the kidney index normalized. Pro-inflammatory TNF-α and IL-6 levels declined, and the previously suppressed IL-4 and IL-10 rose. Histological staining with hematoxylin and eosin, Masson, and PAS revealed that the adriamycin-induced damage, including glomerular atrophy, basement membrane thickening, collagen fiber deposition, and inflammatory cell infiltration, was substantially reversed in the treated animals.

The mechanistic heart of the study lies in its analysis of apoptosis and the TLR4/NF-κB axis. In the diseased rats, apoptotic activity was paradoxically suppressed: Cleaved Caspase-3 staining was weak, TUNEL-positive cells were scarce, and mitochondrial membrane potential measured by JC-1 staining indicated inhibited apoptosis. Western blotting showed downregulation of the pro-apoptotic proteins Bax, cytochrome C, Caspase-9, and Caspase-3, alongside upregulation of the anti-apoptotic Bcl-2. DBD treatment reversed this pattern, restoring pro-apoptotic signaling and promoting the controlled cell death needed to clear damaged glomerular cells. Simultaneously, RT-qPCR, Western blotting, immunohistochemistry, and immunofluorescence all demonstrated that DBD downregulated TLR4, MyD88, IκBα, and NF-κB, damping the inflammatory cascade that LPS and adriamycin normally ignite.

This dual action makes biological sense in light of the disease mechanism. When TLR4 on mesangial cell surfaces is activated, it recruits MyD88, promotes IκB phosphorylation and degradation, and triggers NF-κB nuclear translocation, where the transcription factor drives expression of inflammatory cytokines such as TNF-α and IL-1β and of the anti-apoptotic protein Bcl-2. By suppressing this pathway, DBD reduces inflammatory cytokine release; by simultaneously promoting Bax-mediated cytochrome C release and Caspase-9 and Caspase-3 activation, it restores the apoptotic balance whose disruption drives both pathological mesangial accumulation and loss of kidney filtering cells. The authors note that apoptosis is a double-edged sword, but their data indicate that reactivating it in this context slows disease progression rather than accelerating tissue damage.

The findings carry practical significance beyond the laboratory. Current clinical management of chronic glomerulonephritis relies on angiotensin-converting enzyme inhibitors, corticosteroids, and immunosuppressants, all of which carry limitations including variable drug sensitivity, symptom recurrence, and long-term adverse effects such as hyperkalemia, dry cough, increased infection risk, and digestive reactions. A multi-component, multi-target herbal formula that modulates both inflammation and apoptosis could offer a gentler complementary strategy, and the study’s systematic workflow, from chemical profiling through network prediction to animal and cellular validation, provides a template for scientifically grounding other traditional formulas. The researchers conclude that DBD exerts its therapeutic effects on chronic glomerulonephritis by regulating the TLR4/NF-κB signaling pathway, promoting apoptosis, and alleviating inflammation, laying an experimental foundation for explaining its clinical efficacy in modern pharmacological terms.

Subject of Research: Mechanism of action of Danggui Buxue Decoction in treating chronic glomerulonephritis via the TLR4/NF-κB signaling pathway

Article Title: Exploring the Mechanism of Action of Danggui Buxue Decoction in Treating Chronic Glomerulonephritis Based on UPLC‐MS/MS and Network Pharmacology

Article References: Liu, Q., Wang, Y., Wang, X., Yang, H., Pan, Z., & Guo, D. (2026). Exploring the Mechanism of Action of Danggui Buxue Decoction in Treating Chronic Glomerulonephritis Based on UPLC‐MS/MS and Network Pharmacology. Immunity, Inflammation and Disease, 14(9), Article e70497. https://doi.org/10.1002/iid3.70497

Image Credits: AI Generated

DOI: 10.1002/iid3.70497

Keywords: Danggui Buxue Decoction, chronic glomerulonephritis, network pharmacology, UPLC-MS/MS, TLR4/NF-κB pathway, apoptosis, traditional Chinese medicine, kidney disease, HBZY-1 mesangial cells, molecular docking, inflammation, astragalus